Two-in-one breakthrough: Cutting-edge immunotherapy could hold promise for incurable brain cancer
Posted: 3 September 2024 Researchers at WEHI have identified a promising new two-in-one treatment that not only targets and destroys an aggressive form of brain cancer, but also helps the immune system develop a lasting defence against it. This…
Scientists discover how the body’s killer cells attack cancer
Posted: 3 September 2024 An international team of scientists are on the verge of a cancer breakthrough after working out how the body’s immune system targets cells devastated by the disease. A new study published in the journal Science…
2024 BioSymposium sponsors – Innovating antibody drug conjugates: From mechanisms to market
Web djsir.vic.gov.au/health-tech Email medtech.pharma@ecodev.vic.gov.au About us Victoria is home to world-class health technology companies and is a preferred location for many global leaders including CSL, Moderna, BioNTech, Illumina, Telix Pharmaceuticals and Pfizer. International companies partner with Victoria for its…
Nominations open for BioMelbourne Network’s Women in Leadership Awards 2025
Posted: 2 September 2024 BioMelbourne Network has opened nominations for its Women in Leadership Awards 2025. This prestigious event, now in its 11th year, continues to recognise and champion women who have made outstanding contributions in the healthtech…
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Posted: 28 August 2024 Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characterisation of progressive or…
Finger-prick test could screen for early Alzheimer’s
Posted: 28 August 2024 GPs could soon be able to screen their patients for Alzheimer’s Disease (AD) using a simple handheld device developed by Monash engineers. Monash engineers have developed the first-of-a-kind finger-prick blood test with ‘needle-in-a hay-stack’…
Life prolonging breast cancer drug receives expanded access on the PBS
Posted: 28 August 2024 Australians diagnosed with a type of metastatic breast cancer will now have access to a life prolonging treatment under the Pharmaceutical Benefits Scheme (PBS) from 1 September 2024. Trastuzumab deruxtecan (Enhertu®) will be expanded on…
$66 million in 10 years: groundbreaking strategic investment fund to drive biomedical innovation
Posted: 28 August 2024 With a grand vision of investing $66 million over 10 years in groundbreaking medical innovations, WEHI’s first strategic investment fund, 66ten, is the largest internal pre-seed and seed fund created by an Australian medical…
Delivery of New Colorectal Cancer Multiplex Assay Alpha Kit
Posted: 28 August 2024 Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (Rhythm or the Company) advises it has received the first batch of the Alpha version of the multiplex antibody detection kits developed and…
Lumos Diagnostics seals deal to advance point-of-care test to monitor liver health
Posted: 27 August 2024 Lumos Diagnostics (ASX:LDX) has extended its existing deal with the Burnet Diagnostics Initiative to progress a new point-of-care test for use in monitoring liver health in an upcoming clinical trial. As part of the deal,…
Sleep tight: New wearable sensor sheds light on getting the best rest
Posted: 27 August 2024 In a world first, a new wearable device developed by Monash University researchers will help to record the impact of artificial light on our bodies for sound sleep, improved mental wellbeing and treating chronic…
Structure of a key “trigger” of the immune response solved
Posted: 27 August 2024 An international collaboration, involving researchers from Monash University and the University of Oxford, has led to a breakthrough in our understanding of how immune responses are started. The study has just been published in Nature. The human…
